# ODYSSEE (NCT02928523)

> PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients

No report yet. It can be ordered.

- Indication: acute myeloid leukemia undergoing intensive treatment

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02928523
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: MaaT Pharma
- Conditions: Leukemia, Myeloid, Acute
- Interventions: Autologous Fecal Microbiota Transplantation
- Enrollment: 20
- Primary outcome: Evaluation of AFMT efficacy in dysbiosis correction by measure of microbiota diversity
- Primary outcome: Evaluation of AFMT efficacy in MDRB eradication based on bacterial culture

## Indexed commentary on ODYSSEE so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 YouTube videos
- 1 post on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=odyssee-nct02928523
